• Home
  • News
  • Analysis
  •  
    Regions
    • Australasia
    • Southeast Asia
    • Greater China
    • North Asia
    • South Asia
    • North America
    • Europe
    • Central Asia
    • MENA
  •  
    Funds
    • LPs
    • Buyout
    • Growth
    • Venture
    • Renminbi
    • Secondary
    • Credit/Special Situations
    • Infrastructure
    • Real Estate
  •  
    Investments
    • Buyout
    • Growth
    • Early stage
    • PIPE
    • Credit
  •  
    Exits
    • IPO
    • Open market
    • Trade sale
    • Buyback
  •  
    Sectors
    • Consumer
    • Financials
    • Healthcare
    • Industrials
    • Infrastructure
    • Media
    • Technology
    • Real Estate
  • Events
  • Chinese edition
  • Data & Research
  • Weekly Digest
  • Newsletters
  • Sign in
  • Events
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)870 240 8859

      Email: customerservices@incisivemedia.com

      • Sign in
     
      • Saved articles
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • RSS
    • Twitter
    • LinkedIn
    • Newsletters
  • Free Trial
  • Subscribe
  • Weekly Digest
  • Chinese edition
  • Data & Research
    • Latest Data & Research
      2023-china-216x305
      Regional Reports

      The reports review the year's local private equity and venture capital activity and are filled with up-to-date data and intelligence on fundraising, investments, exits and M&A. The regional reports also feature information on key companies.

      Read more
      2016-pevc-cover
      Industry Review

      Asian Private Equity and Venture Capital Review provides an independent overview of the private equity, venture capital and M&A activities in the Asia region. It delivers insights on investments made, capital raised, sector specific figures and more.

      Read more
      AVCJ Database

      AVCJ Database is the ultimate link between Asian dealmakers and those who provide advisory, financial, legal and technological services to the private equity, venture capital and M&A industries. It is packed with facts and figures on more than 153,000 companies and almost 117,000 transactions.

      Read more
AVCJ
AVCJ
  • Home
  • News
  • Analysis
  • Regions
  • Funds
  • Investments
  • Exits
  • Sectors
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)870 240 8859

    Email: customerservices@incisivemedia.com

    • Sign in
 
    • Saved articles
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 

China

Weekly digest - April 27 2022
Weekly digest - April 27 2022

  • Region
  • 27 April 2022
China RPA player Shadowbot raises $100m
China RPA player Shadowbot raises $100m

Shadowbot, a China-based robotic process automation (RPA) service provider, has raised USD 100m in its Series C funding led by Goldman Sachs and an undisclosed corporate venture capital investor.

  • Greater China
  • 27 April 2022
Profile: WestSummit Capital's Raymond Yang
Profile: WestSummit Capital's Raymond Yang

Raymond Yang’s rich entrepreneurial experience in China and the US led to the formation of WestSummit Capital. He continues to draw on this knowledge as technology ecosystems evolve

  • Greater China
  • 27 April 2022
China digital CRO Elixir raises $52m

Elixir, a China-based clinical research organisation (CRO), has raised a USD 52m Series A round from Lyfe Capital, Chow Tai Fook Investment, and Sinovation Ventures.

  • Greater China
  • 26 April 2022
China virotherapy specialist Binhui Biopharm raises $47m
China virotherapy specialist Binhui Biopharm raises $47m

Binhui Biopharm, a Chinese biotech firm specialising in oncolytic virus immune-oncology, has raised CNY 300m (USD 47m) in an extended Series B round led by Yangtze River Pharmaceutical Group.

  • Greater China
  • 25 April 2022
China automation specialist Laiye raises $70m

Laiye Technology, a Chinese artificial intelligence (AI) start-up specialising in robotic process automation (RPA), has raised another extension - of USD 70m - to its Series C round. Hopu Investment took the lead.

  • Greater China
  • 21 April 2022
China stem cell drug developer Baylx raises $47m
China stem cell drug developer Baylx raises $47m

Baylx, a Beijing-based drug developer that utilises stem cell technology, has raised CNY 300m (USD 47m)across two rounds - a Series B and a Series B extension.

  • Greater China
  • 19 April 2022
Weekly digest - April 13 2022
Weekly digest - April 13 2022

  • Region
  • 13 April 2022
China consumer: Brand power vs traffic might
China consumer: Brand power vs traffic might

Private equity investment in China’s consumer sector has fluctuated over the past 18 months in line with the fortunes of portfolio companies. Applying TMT logic to brand building didn’t help

  • Greater China
  • 13 April 2022
China game engine developer Cocos raises $50m
China game engine developer Cocos raises $50m

Cocos Technology, a China-based game engine developer, has raised USD 50m in Series B round from CCB Trust, GGV Capital, and voice and video communication platform Agora.

  • Greater China
  • 13 April 2022
Sequoia targets USD 7.1bn for latest China vintage

Sequoia Capital has defied a difficult China fundraising environment to set a target of USD 7.1bn for its latest set of funds, which include an expansion vehicle in addition to the existing growth strategy.

  • Greater China
  • 13 April 2022
China metaverse infrastructure start-up raises $130m
China metaverse infrastructure start-up raises $130m

Chinese metaverse start-up Xmov has raised USD 130m in Series B and Series C funding featuring SoftBank Vision Fund, Sequoia Capital China, Northern Light Capital, and Index Ventures.

  • Greater China
  • 12 April 2022
Hosen closes $280m single asset continuation fund for Kilcoy
Hosen closes $280m single asset continuation fund for Kilcoy

Hosen Capital, which makes investments in China’s consumer space, has closed a USD 280m single-asset continuation fund for Kilcoy Global Foods, a beef processing business it has owned since 2013.

  • Australasia
  • 11 April 2022
China's XVC raises $274m for third US dollar fund

Beijing-based venture capital firm XVC has raised USD 274m for its third US dollar-denominated vehicle. It brings overall assets under management to USD 1.2bn.

  • Greater China
  • 08 April 2022
China's METiS Pharmaceuticals raises $150m
China's METiS Pharmaceuticals raises $150m

METiS Pharmaceuticals, a Hangzhou-based drug formulation company has raised USD 150m through two funding rounds led by PICC Capital and China Life PE.

  • Greater China
  • 07 April 2022
Weekly digest - April 06 2022
Weekly digest - April 06 2022

  • Region
  • 06 April 2022
China cybersecurity provider ThreatBook raises $47m
China cybersecurity provider ThreatBook raises $47m

Beijing-based cybersecurity solutions provider ThreatBook has raised CNY 300m (USD 47m) in an extended Series E round led by CDH Investments, featuring existing investor Star Road Ventures.

  • Greater China
  • 04 April 2022
China MSME financier raises $70m
China MSME financier raises $70m

Micro Connect, a China-based provider of financing to micro, small and medium-sized enterprises (MSMEs), has raised USD 70m in Series B funding.

  • Greater China
  • 01 April 2022
Alibaba leads Series C extension for China AR start-up Nreal

Nreal, a Chinese manufacturer of augmented reality (AR) glasses that resemble normal sunglasses, has raised an extended Series C of USD 60m led by Alibaba Group.

  • Greater China
  • 31 March 2022
Weekly digest - March 30 2022
Weekly digest - March 30 2022

  • Region
  • 30 March 2022
CDH, Huaxing lead $120m Series B for China's InnoRNA
CDH, Huaxing lead $120m Series B for China's InnoRNA

CDH Investments and Huaxing Healthcare Fund have led a USD 120m Series B for InnoRNA, a China-based mRNA drug developer. Existing investors CPE and Fangyuan Capital re-upped.

  • Greater China
  • 30 March 2022
China EV maker Eezi raises $78m
China EV maker Eezi raises $78m

Shenzhen-based electronic vehicle (EV) manufacturer Eezi has raised a CNY 500m (USD 78m) pre-A round led by China Merchants Venture.

  • Greater China
  • 30 March 2022
Deal focus: Jade Invest rides pest control M&A boom
Deal focus: Jade Invest rides pest control M&A boom

Having offered a blueprint for pest control consolidation globally in Anticimex, EQT wants to repeat the trick in China with Guardian Hygiene Service. It meant a 3.3x return for previous owner Jade Invest

  • Greater China
  • 29 March 2022
Investment becomes Tencent's main profit driver in 2021

Investment accounted for the bulk of Tencent Holdings' annual profit for the first time in 2021 as the Chinese technology giant saw earnings from its core business contract in the second half of the year.

  • Greater China
  • 29 March 2022
262728
  • About AVCJ
  • Advertise
  • Contacts
  • About ION Analytics
  • Terms of use
  • Privacy policy
  • Group disclaimer
  • RSS
  • Twitter
  • LinkedIn
  • Newsletters

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013